The Secret is the Secretions
Stem cells hold great promise, but is it the cells we really need?
Nicolas Sohl |
Ophthalmology is full of advances, but sometimes the field is very conservative. Look at the extended-release drug delivery systems that have made it to market: Vitrasert, Ozurdex, Retisert, Iluvien. New drug delivery technology, but really old drugs (ganciclovir, dexamethasone, and fluocinolone acetonide). I think it’s clear that the use of steroids for the treatment of retinal disease will diminish – their drawbacks and side-effects are well-known, and there’s (hopefully) better therapeutic approaches on the horizon.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!